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Abstract
Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related 
osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. 
Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ 
in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied dur-
ing the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide. All 
the cases of BRONJ should meet the following conditions: recurrent BRONJ, impossibility of surgery in stage 3 
Ruggiero classification and absence of diagnosed neoplastic disease. Clinical and radiographic evolution of the 
patients from both groups was observed.
Results: Nine patients were included, 5 in group A and 4 in group B. All the patients were women on oral bis-
phosphonate therapy for primary osteoporosis (5 patients) or osteoporosis-related to the use of corticosteroids 
(4 patients). Alendronate was the most common oral bisphosphonate associated with BRONJ in our study (four 
patients in group A and two in group B). The mean age was 72,8 years in the group A and 73,5 years in the group 
B. All the patients from group A showed a complete resolution of their BRONJ. Only one patient in the group B 
showed the same evolution.
Conclusions: In our series, the plasma rich in growth factors showed better results than the teriparatide in the 
treatment of recurrent BRONJ.
Key words: Osteonecrosis, oral bisphosphonate, treatment, teriparatide, plasma rich in growth factors.
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Introduction
Since Marx first established a connection between the 
use of bisphosphonates for malignant bone diseases and 
the occurrence of necrotic bone in the oral cavity in 2003 
(1), numerous studies have been published concerning 
the disease that soon became known as Bisphospho-
nate-Related Osteonecrosis of the Jaws (BRONJ) (2,3). 
The management of patients with BRONJ remains chal-
lenging because surgical and medical interventions may 
not eradicate this process. The goal of treatment of pa-
tients at risk of developing BRONJ, or for those who 
have active disease, is preservation of quality of life by 
controlling pain, managing infection, and preventing 
the development of new areas of necrosis (4). Not only 
the pathogenesis is still not fully understood, but also 
the treatment of BRONJ remains problematic and the 
outcome is often unknown (5,6). 
For these reasons, different authors justify the appli-
cation of alternative treatments, including hyperbaric 
oxygen (7), fluorescence-guided bone curettage (8), low 
intensity laser (9) and local flaps using buccal fat pad 
(10), but with no conclusive results.
The subcutaneous administration of teriparatide hor-
mone (rhPTH1–34) (11,12) and the surgical application 
of plasma rich in growth factors (PRF) (13,14) in the 
surgical site constitute two new alternative forms of 
BRONJ treatment that should be evaluated.
The aim of this study is to describe and compare the 
evolution of BRONJ’s patients treated with plasma rich 
in growth factors (Group A) or teriparatide (Group B).
Material and Methods
- Patients
The study was carried out with BRONJ patients be-
longing to a single hospital (reference for a population 
of 1.100.000 inhabitants) diagnosed and/or treated be-
tween January 2010 and December 2012. All patients 
must meet the following criteria: recurrent BRONJ af-
ter application of the protocol treatment proposed by 
AAOMS (15), impossibility of recommended surgery 
in stage 3 of classical classification (16) of BRONJ by 
poor general condition of the patient, absence of diag-
nosed neoplastic disease and lack of jaw radiotherapy 
medical history. All the patients were treated with PRF 
(approximately 7 ml in each patient) or teriparatide (20 
μg once daily for each patient).
All the patients included in Group A had recurrences 
after previous surgeries with adverse outcome. A single 
surgeon (LJ) performed all the surgeries and applied the 
PRF in these patients. Post-surgical antibiotherapy was 
prescribed to all patients with amoxicilin/clavulanic 
acid (4 g/day) during 15 days. The patients were checked 
every 15 days during the following three months. 
On the other hand, the group B consisted by those pa-
tients who had recurrences after a previous surgery and/
or whose condition was generally impossible for the ap-
plication of a new surgery. All the patients treated with 
teriparatide were previously evaluated by a specialist of 
the Bone and Mineral Metabolism Unit (CG), ruling out 
the presence of hypercalcaemia or unexplained eleva-
tion of alkaline phosphatase. 
- Types of treatment
A. Plasma rich in growth factors 
In order to obtain this plasma, it was used Vivostat 
PRF® system. Every patient was operated with general 
anesthesia or with local anesthesia and conscious seda-
tion. During the surgery, 120 ml of blood were extract-
ed. The Vivostat PRF® system is an automated, closed 
and sterile system that allows obtaining a platelet con-
centration ten times higher than the basal level and a 
fibrin concentration around 18.1 ng/ml. 
Before the application of plasma with a pen sprayer, 
the bone sequestrations were removed and curettage 
was performed in the bone tissue until clear bleeding 
appeared from the subjacent bone (Fig. 1). The bone 
cavity was filled with the plasma obtained. A thorough 
hermetic close of the overlying oral mucosa was made 
with resorbable suture of 4/0 polyglycolic acid without 
tension in all the cases. Over the suture, a new layer of 
the product was also sprayed. The number of patients 
with this treatment was 5. For each patient were used 
about 7 ml of plasma rich in growth factors.
Fig. 1. Case A2. Mandibular bone defect after 
sequestrectomy (A) filled with PRF (B). The 
mucosal wound is also covered with PRF (C).
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B. Teriparatide administration
Teriparatide (Forsteo®, 20 μg once daily by self-ad-
ministered subcutaneous injection) was initiated at the 
baseline visit, and women attended monthly follow-up 
visits up to 6 months after discontinuing the teriparatide 
treatment. The maximum time of teriparatide adminis-
tration was restricted to 10 months.
Results
- Plasma rich in growth factors 
Table 1 shows the main characteristics of the five pa-
tients belonging to the group with this treatment. The 
mean age was 72,8 years. All of them were women 
treated with oral bisphosphonates for osteoporosis. The 
drug most commonly used was the alendronate (4 cas-
es). In four of the patients the exposed bone was located 
in the mandible. Three patients had a history of tooth 
extraction before the development of BRONJ and four 
patients had been previously treated with surgery in our 
hospital without success. In one patient, the bone expo-
N AGE SEX Medical condition
Bisphosphonate 
and dosis 
administered
Localization Concomitanttreatments Trigger
Current  
Status Comments
A1 F 82 
Osteoporosis
Rheumatoid 
Arthritis 
Ibandronate,
Monthly 
42 months 
6300 mg 
Mandibular 
Posterior 
Corticosteroids 
Methotrexate 
Trauma     
Prosthetic 
Complete 
Resolution 
-Lip Anesthesia 
-Previous surgery 
-16 months of 
follow-up.
A2 F 60 Osteoporosis 
Alendronate,
Weekly 
42 months 
127490 mg 
Maxilar 
Posterior 
Antihypertensive 
Anxiolytics 
Dental
extraction 
Complete 
Resolution 
-Oro-antral
communication 
-Previous surgery 
-24 months of 
follow-up.
A3 F 64 Osteoporosis 
Alendronate,
Weekly 
84 months 
25840 mg 
Mandibular 
Posterior Anxiolytics 
Dental
extraction 
Complete 
Resolution 
-Previous surgery 
-24 months of 
follow-up.
A4 F 71 
Osteoporosis
Rheumatoid 
Arthritis 
Alendronate,
Weekly 
60 months 
18200 mg 
Mandibular 
Anterior 
Corticosteroids 
Methotrexate 
Dental      
extraction 
Complete 
Resolution 
-24 months of 
follow-up.
A5 F 87 Osteoporosis 
Alendronate,
Weekly 
48 months 
14560 mg 
Mandibular 
Anterior 
Antihypertensive 
Anxiolytics 
Dental
implant. 
Complete 
Resolution 
-Previous surgery 
-12 months of 
follow-up.
Table 1. Summary of the patients treated with plasma rich in grow factors (PRF).
sure was located in the mandibular incisive region (Fig. 
2) and had received no surgical treatment before appli-
cation of PRF (Vivostat®). This patient not only had a 
previous history of multiple spontaneous expulsions of 
sequestered bone, but also the presence of active drain-
age at the time of diagnosis. The recovery of the disease 
was observed in all patients, with a complete resolu-
tion of the symptoms including the bone exposure. The 
average control time was 20 months (range: 12 to 24 
months).
- Teriparatide
The main information from group B of patients is re-
sumed in table 2. All of them were also women, with a 
mean age of 73.5 years. All the BRONJ were located in 
the mandible. Two patients had suffered a tooth extrac-
tion before the presentation of the BRONJ and had been 
subjected to sequestrectomy unsuccessfully in our ser-
vice. Because of their general condition (severe neuro-
degenerative disease) the remaining two patients were 
excluded to any kind of surgical intervention. During 
the treatment, all patients were clinically and biochemi-
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Fig. 2. Case A4. Mandibular BRONJ with purulent sinus tract high-
lighted with an arrow (A). Computed tomography (B) shows the os-
teolytic pattern affecting the incisive mandibular area.
Table 2. Main characteristics of the patients treated with teriparatide.
N AGE SEX Medical condition
Bisphosphonate 
and dosis 
administered
Localization Concomitanttreatments Trigger
Current 
status Comments
B1 64 F Osteoporosis 
Alendronate,
Weekly 
72 months 
21840 mg 
Mandibular 
Posterior -
Dental
extraction 
Complete 
Resolution 
- 4 months of 
treatment with 
teriparatide. 
- Previous surgery 
- 18 months of 
follow-up.
B2 68 F 
Osteoporosis
Rheumatoid 
Arthritis 
Alendronate,
Weekly 
48 months 
14560 mg 
Mandibular 
Anterior 
Corticosteroids 
Antihypertensive 
Anxiolytics 
Dental
extraction 
Symptomatic 
Bone
Exposure
- 10 months of 
treatment with 
teriparatide. 
- Previous surgery 
- 24 months of 
follow-up.
B3 84 F Osteoporosis 
Ibandronate,
Monthly 
42 months 
6300 mg 
Mandibular 
Anterior - Spontaneous 
Asymptomatic 
Bone
Exposure
-7 months of 
treatment with 
teriparatide. 
-12months of 
follow-up.
B4 78 F 
Osteoporosis
Rheumatoid 
Arthritis 
Ibandronate,
Monthly 
48 months 
7200 mg 
Mandibular 
Posterior Corticosteroids Spontaneous 
Asymptomatic 
Bone
Exposure
-6 months of 
treatment with 
teriparatide. 
-14 months of 
follow-up.
cally evaluated by the Bone and Mineral Metabolism 
Service. In the two patients without previous surgery, 
pain and infection were controlled (Fig. 3), but remained 
the bone exposure. 
Regarding to the two patients with clinical history of 
recurrence after previous surgeries different outcomes 
were observed. One of them did not show any improve-
ment with persistent symptomatic bone exposure after 
ten months of drug administration. Finally, the last 
patient developed a favorable outcome with complete 
resolution of the bone exposure after the removal of an 
additional bone sequestrum and associating a negative 
adherence to the teriparatide treatment abducting psy-
chological problems. The teriparatide administration 
ranged from 4 to 10 months with an average control 
time of 17 months (range: 12 to 24 months).
Discussion
Dohan Ehrenfest et al. (17) divided the platelet concen-
trates in four different types according to their leucocytes 
and fibrin content. In our study, fibrin rich in growing 
factors was used as filling material, using the technolo-
gy of Vivostat PRF® system, with good results and long 
control time. In 2007 some observational studies were 
published about a reduced number of BRONJ patients 
who had been treated with PRF with irregular results 
(18-20). Recently, Bocanegra-Pérez et al. (13) published 
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Fig. 3. Case B3. Asymptomatic bone exposure after 7 months of 
treatment with teriparatide.
a series of 8 patients treated with platelet-rich plasma 
and leucocytes (Smart PReP®) showing an improvement 
of their lesions after a month with the treatment and also 
without bone exposure after 14 months. According to 
these authors, at least 2 of the 19 cases published with 
this treatment did not show any improvement, but the 
type of product employed is not uniform and the con-
trol time is often too short (less than 6 months). Very 
recently, Mozzati M et al. (14) have published an inter-
esting essay that claims a 100% of success (complete 
healing) in 32 patients with chemical osteonecrosis, 24 
of them in the mandible. Control time in the study was 
around 48-50 months. These authors used the technique 
described by Anitua, which also documented a BRONJ 
case treated successfully with PRF (21). Our observa-
tions show satisfactory results too although we had less 
cases and we used PRF. Moreover, it is important to 
note not only four of our patients treated this way had 
had been previously treated with surgery without suc-
cess, but also three of the patients successfully treated 
with PRF wore more than one year of evolution of their 
BRONJ.
Lately, parathyroid human hormone (PTH) has been 
approved for the treatment of osteoporosis in two dif-
ferent presentations, 1-34 active fraction (Teriparatida, 
Forsteo®) and intact molecule (PTH, Protact®) identic 
to the natural complete hormone (and 84 aminoacid 
polypeptide). Teriparatide, recombinant human N-ter-
minal fragment of parathyroid hormone, is a bone ana-
bolic agent shown to increase bone mass and strength 
and reduces the incidence of vertebral and non-vertebral 
fractures in post-menopausal women with osteoporosis. 
The European Forsteo Observational Study (EFOS) 
was a prospective observational cohort study of wom-
en treated with teriparatide in eight western European 
countries. The primary objective of this study was to 
determine the incidence of clinical vertebral and non-
vertebral fractures in post-menopausal women with os-
teoporosis treated with teriparatide for 18 months, with 
a post-treatment follow-up of 18 months. The results for 
the full cohort pooled across countries have recently 
been published (22). Recommended dose is 20 μg once 
a day subcutaneously into the thigh or abdomen during 
a maximum of 18 months. At this moment, despite its 
high cost (more than 5000 euros per year), it does not 
show better results than the regular alendronate treat-
ment (23).
In October 2010, a prestigious international journal 
published a randomized, unicentric, double-blind study 
in which were compared the effects on the alveolar 
process of 40 patients with severe periodontal disease 
treated with 20 μg of teriparatide versus placebo dur-
ing 6 weeks. After one year of clinical monitoring, the 
drug efficacy was proved (24). In the same number of 
this journal, other authors (11) documented an interest-
ing case of an 88 year-old woman with an osteonecro-
sis caused by oral bisphosphonates with 12 months of 
evolution who had had no response to the regular treat-
ment, including curettage. After starting with a 20-μg/
day teriparatide treatment, clinical and radiographic 
resolution was shown at the 8th week of treatment.
More recently, Kwon et al. (25) published a work about 6 
patients with osteonecrosis caused by oral bisphospho-
nates who were treated with teriparatide and showed the 
spontaneuos recovery of one of the patients after three 
months of treatment. The other 5 would also have a total 
recovery after practising surgery and antibiotherapy in 
a period not longer than three months. In this work, the 
only resolved case without another type of treatment but 
teriparatide was located in the upper jaw (the rest in the 
mandible). 
In March 2012, Narváez et al. (26) reviewed all the 
cases published about BRONJ treated with teriparatide. 
They concluded that there were only six cases published 
(excluding the serie from Kwon et al.) (25) regarding 
osteonecrosis related to oral bisphosphonates (mostly 
alendronate). All of them presented a clinical and radio-
graphic recovery (27-30). Teriparatide was given dur-
ing 4-10 months. In 4 of the reviewed cases the factor 
that triggered the osteonecrosis was a dental extraction 
while in 2 cases was the placement of an implant. In 
their study, Narvaez et al. (26) give evidence of a 79 
year-old patient with reumatoid arthritis with no previ-
ous surgery who did not show a resolution after being 
treated for 8 months with teriparatide. 
In summary, 13 patients have been reviewed in the lit-
erature with oral bisphosphonate osteonecrosis who 
received subcutaneous teriparatide as treatment. In 12 
of them clinical and radiologic recovery is referred and 
just in one the evolution could not be confirmed. In some 
cases, the osteonecrosis recovery was reached only with 
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exclusive teriparatide treatment while in other ones it 
was necessary to combine bone anabolizant factor with 
antibiotics and surgery. According to this, it seems that 
the use of teriparatide as BRONJ treatment is still lim-
ited and that it has a low scientific evidence level.
It is paramount not to ignore the use of teriparatide is 
contraindicated in patients with metastatic cancer be-
cause of its participation in the promotion of metastasis 
and, furthermore, according to the FDA, its administra-
tion time may not be longer than 18 months, in rela-
tion to a possible osteosarcoma development (noticed 
in mice). 
Our series details the less favorable results about the 
use of teriparatide in BRONJ reported in the literature; 
however, the patient choice was not randomized. We 
included two patients in which the protocol treatment 
proposed by AAOMS (15) had failed. One of those, with 
reumatoid arthritis treated concurrently with corticoids 
and methotrexate, did not present an improvement after 
10 months of teriparatide treatment. The other patient, 
without concurrent diseases, a complete resolution was 
shown after practicing a new surgery after ending teri-
paratide treatment. Two people whose bad general con-
dition did not indicate surgery formed the other patient 
group included in our study. In these two patients a total 
recovery of the BRONJ was neither reached after 7 and 
6 months of teriparatide.
In conclusion, in our series the plasma rich in growth 
factors showed better results than the teriparatide in the 
treatment of recurrent BRONJ.
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